EPHA2 and neoplasm: For instance, Muhammad et al. synthesized a novel TanCAR, comprising a tandem arrangement of IL13 and EphA2 single-chain variable fragments (scFv), demonstrating that the IL13-anti-EphA2 TanCAR exhibited markedly stronger anti-tumor efficacy compared to single CAR-T cells, both in vitro and in vivo [52].